AVOCOM OINT 0.1% 30G

Indications

Approved Uses

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis and psoriasis).

Off-Label Uses

Off-label examples: seborrheic dermatitis (short courses), chronic hand eczema, lichen simplex chronicus/lichen planus (including oral specialist use), vitiligo (adjunct), alopecia areata (limited evidence).

Dosage & Administration

Dosing by Condition

For corticosteroid-responsive dermatoses (including atopic dermatitis and psoriasis): apply a thin film once daily; avoid routine occlusion, and if used for thick/resistant plaques, occlusion should be short-term and clinician-directed only.

Initial Dose

Apply a thin layer to the affected skin area once daily

Maintenance Dose

Apply a thin film to the affected skin area once daily. Therapy should be discontinued when control is achieved.

Maximum Dose

Apply a thin layer once daily; avoid prolonged continuous use and avoid large-area application-reassess if not improved within ~2 weeks (especially for potent steroids).

Dose Adjustment Notes

Use the lowest effective amount for the shortest duration; once controlled, step down by reducing frequency (e.g., intermittent/alternate-day) or switch to a lower-potency steroid; if no improvement within ~2 weeks, reassess diagnosis/adherence and consider alternative therapy.

How to Take

Topical use: apply a thin film to affected skin once daily and rub in gently; wash hands before and after (unless treating hands); avoid eyes and other mucous membranes; do not apply to face/groin/axillae or broken/infected skin unless directed; avoid occlusive dressings/bandaging unless prescribed.

Side Effects

Common Side Effects

Application-site burning/stinging/tingling, pruritus, dryness/irritation; with prolonged use: skin atrophy, striae, telangiectasia, folliculitis/acneiform eruptions, hypertrichosis, hypopigmentation, perioral dermatitis, secondary infection (rarely furunculosis).

Side Effect Frequency

Common: application-site burning/stinging/itching/irritation; Uncommon/less common: folliculitis/furunculosis, acneiform eruptions, hypopigmentation, allergic contact dermatitis, perioral dermatitis, hypertrichosis, striae/skin atrophy (risk increases with prolonged/occlusive use); Rare: systemic corticosteroid effects including HPA-axis suppression/Cushingoid features, hyperglycemia, and (especially in children) intracranial hypertension.

Safety & Warnings

Warnings & Precautions

Avoid eyes/mucosa and periocular use; do not use under occlusion unless directed; use the minimum effective amount for the shortest duration and avoid large areas; higher systemic-toxicity risk in children; avoid/appropriately treat infected dermatoses; monitor for skin atrophy/striae (especially face/intertriginous areas) and for ocular adverse effects if used near eyes.

Age Restriction

Not recommended in children under 2 years of age.

Drug Interactions

Interaction Severity

MODERATE: Occlusive dressings/large-area use (increases systemic absorption and HPA-axis suppression risk); MODERATE: strong CYP3A4 inhibitors (e.g., ritonavir/cobicistat, ketoconazole/itraconazole) may increase systemic corticosteroid effects if absorption is significant.

Food Interaction

No clinically relevant food interactions for topical mometasone; grapefruit avoidance is not routinely required.

Special Populations

Kidney Impairment

No adjustment needed

Storage & Patient Advice

Overdose

Excessive/prolonged use (especially under occlusion/large areas) may cause local atrophy/striae and systemic effects including HPA-axis suppression/Cushingoid features; management is to stop or taper and provide supportive care, with monitoring for adrenal insufficiency if significant exposure.

Patient Counseling

Apply a thin layer to affected skin once daily (or as prescribed) and use the smallest amount for the shortest duration; avoid eyes/mucosa and wash hands after use; do not use on face/groin/axillae or on broken/infected skin unless directed; avoid occlusive dressings unless prescribed; stop when control is achieved and seek medical advice if worsening, signs of infection, or steroid adverse effects (skin thinning/striae) occur; do not share-this is prescription-only (per SFDA legal status).

Monitoring Requirements

Monitor for local adverse effects (atrophy, striae, telangiectasia, dermatitis, infection) and treatment response; consider HPA-axis suppression monitoring in high-risk use (large surface area, prolonged therapy, occlusion, pediatric patients).

Pharmacology

Mechanism of Action

Topical glucocorticoid: binds intracellular glucocorticoid receptors to alter gene transcription, inducing lipocortins that inhibit phospholipase A2 and reducing prostaglandin/leukotriene production, producing anti-inflammatory, antipruritic, and vasoconstrictive effects.

Onset of Action

Within hours for reduction in itching/redness; noticeable improvement typically within 1-2 days.

Duration of Effect

Approximately 24 hours per application (supports once-daily use); clinical benefit persists with continued daily use.

Bioavailability

Minimal systemic absorption on intact skin without occlusion (typically <1%); absorption increases with inflammation, broken skin, large surface area use, prolonged therapy, or occlusion.

Excretion

After systemic absorption, metabolites are eliminated mainly via bile/feces with a minor renal component (exact proportions after topical use are not well quantified).

Product Information

Available Dosage Forms

Ointment, cream, lotion/solution (topical); nasal spray exists as a separate product/indication (allergic rhinitis).

Composition per Dose

Each gram of ointment: 1 mg mometasone furoate (0.1%) in a white petrolatum base

OTC Alternatives

Hydrocortisone 1% topical (cream/ointment) for mild inflammatory dermatoses; plus non‑steroidal OTC supportive options such as regular emollients/moisturizers (and barrier creams) for dryness/irritation.

Skin Condition

Eczema, Psoriasis

Steroid Potency

Potent

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.